Teva Pharmaceutical Industries is an international pharmaceutical company headquartered in Petah Tikva, Israel that specializes in generic drugs and active ingredients.
Recently, the pharmaceutical company announced a collaboration with the biotechnology company Immunai Inc. to advance immunology and immuno-oncology programs, more specifically in the development of drugs using artificial intelligence.
Immunai develops novel therapies by combining single-cell genomics and machine learning to decode the immune system. According to Noam Solomon, CEO of the company, the collaboration seeks to address the challenge of developing drugs, a “challenging, long and expensive” process.
He added that “through our partnership with Teva, we look forward to using our AI-based engine, the Immunodynamics Engine (IDE)™, to streamline this process and facilitate the delivery of new therapies to patients.”